Philip Ninan

Philip Ninan

Auto-generated profile, based on publicly available information

Philip Ninan

Mood and Anxiety Disorders Program, Emory University School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Biological Psychiatry
Verified
Journal Article
Closed access
ARA.John Rush
A.John Rush
MTMadhukar H Trivedi
Madhukar H Trivedi
HIHicham M Ibrahim
Hicham M Ibrahim
TCThomas J Carmody
Thomas J Carmody
BABruce Arnow
Bruce Arnow
MKMartin B Keller
Martin B Keller

13 November 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CNCharles B. Nemeroff
Charles B. Nemeroff
CHChristine Heim
Christine Heim
MTMichael E. Thase
Michael E. Thase
DKDaniel N. Klein
Daniel N. Klein
ARA. John Rush
A. John Rush
MKMartin B. Keller
Martin B. Keller
Major depressive disorder is associated with considerable morbidity, disability, and risk for suicide. Treatments for depression most commonly include antidepressants, psychotherapy, or the combination. Little is known about predictors of treatment response for depression. In this study, 681 patients with chronic forms of major depression were treated with an antidepressant (nefazodone), Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or the combination. Overall, the effects of the antidepressant alone and psychotherapy alone were equal and significantly less effective than combination treatment. Among those with a history of early childhood trauma (loss of parents at an early age, physical or sexual abuse, or neglect), psychotherapy alone was superior to antidepressant monotherapy. Moreover, the combination of psychotherapy and pharmacotherapy was only marginally superior to psychotherapy alone among the childhood abuse cohort. Our results suggest that psychotherapy may be an essential element in the treatment of patients with chronic forms of major depression and a history of childhood trauma.

21 June 2006 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
ARA John Rush
A John Rush
HKHelena C Kraemer
Helena C Kraemer
HSHarold A Sackeim
Harold A Sackeim
MFMaurizio Fava
Maurizio Fava
MTMadhukar H Trivedi
Madhukar H Trivedi
ASAlan F Schatzberg
Alan F Schatzberg
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are preferred as they provide a more certain ascertainment of remission. These recommendations were based largely on logic, the need for internal consistency, and clinical experience owing to the lack of empirical evidence to test these concepts. Research to evaluate these recommendations empirically is needed.

1 September 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
ARA. John Rush
A. John Rush
HSHarold A. Sackeim
Harold A. Sackeim
LMLauren B. Marangell
Lauren B. Marangell
MGMark S. George
Mark S. George
SBStephen K. Brannan
Stephen K. Brannan
JBJohn J. Barry
John J. Barry

1 September 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
MGMark S. George
Mark S. George
ARA. John Rush
A. John Rush
LMLauren B. Marangell
Lauren B. Marangell
HSHarold A. Sackeim
Harold A. Sackeim
SBStephen K. Brannan
Stephen K. Brannan
PGPaul Goodnick
Paul Goodnick

24 December 1982 in Science
Verified
Journal Article
Closed access
PDF file
PNPhilip T. Ninan
Philip T. Ninan
TIThomas M Insel
Thomas M Insel
RCRobert M. Cohen
Robert M. Cohen
JCJames M. Cook
James M. Cook
PSPhil Skolnick
Phil Skolnick
SPSteven M. Paul
Steven M. Paul
The ethyl ester of β-carboline-3-carboxylic acid has a high affinity for benzodiazepine receptors in the brain. In the rhesus monkey this substance produces an acute behavioral syndrome characterized by dramatic elevations in heart rate, blood pressure, plasma cortisol, and catecholamines. The effects are blocked by benzodiazepines and the specific benzodiazepine receptor antagonist Ro 15-1788. The benzodiazepine receptor may consist of several subsites or functional domains that independently recognize agonists, antagonists, or "active" antagonists such as β-carboline-3-carboxylic acid ethyl ester. These results suggest that the benzodiazepine receptor is involved in both the affective and physiological manifestations of anxiety, and that the administration of β-carboline-3-carboxylic acid ethyl ester to monkeys may provide a reliable and reproducible animal model of human anxiety.